Table 3 Health impacts, annual costs and benefits from reducing chlordecone exposures in Guadeloupe (Without threshold)
Health outcome | Main source of variation | Population at risk | Period of exposure measurement | n | Impact (mean estimate) | CI low (€2006) | CI mean (€2006) | CI high (€2006) | Proportion (mean estimate) |
|---|---|---|---|---|---|---|---|---|---|
Liver cancer | Conversion from ingestion dose to blood chlordecone | All | <2003 | 436 968 | 5.4 | 8 821 000 | 13 129 000 | 26 874 000 | 34Â % |
≥2003 | 458 465 | 2.0 | 3 274 000 | 4 873 000 | 9 974 000 | 21 % | |||
Annual benefit |  | −3.4 | 5 547 000 | 8 256 000 | 16 900 000 | 56 % | |||
Prostate cancer | IC95% of RR | Men > 44 years | <2003 | 72 566 | 2.8 | 1 405 000 | 5 152 000 | 10 572 000 | 13 % |
≥2003 | 76 049 | 1.0 | 490 000 | 1 797 000 | 3 687 000 | 8 % | |||
Annual benefit |  | −1.8 | 915 000 | 3 355 000 | 6 885 000 | 23 % | |||
Renal dysfunction | BMD10-HED | Women | <2003 | 227 417 | 0.10 | 27 000 | 308 000 | 769 000 | 0.80Â % |
≥2003 | 239 470 | 0.04 | 11 000 | 128 000 | 320 000 | 0.54 % | |||
Annual benefit |  | −0.06 | 16 000 | 180 000 | 449 000 | 1.23 % | |||
Cognitive development | Equivalence between QI point and ASQ point | Male new born | <2003 | 3 747 | 1 173 | 3 949 000 | 19 745 000 | 39 489 000 | 52 % |
≥2003 | 3 929 | 1 003 | 3 377 000 | 16 887 000 | 33 773 000 | 71 % | |||
Annual benefit |  | −168 | 572 000 | 2 858 000 | 5 716 000 | 20 % | |||
Total |  |  | <2003 |  |  | 14 202 000 | 38 334 000 | 77 704 000 | 100 % |
≥2003 |  |  | 7 152 000 | 23 685 000 | 47 754 000 | 100 % | |||
Annual benefit |  |  | 7 050 000 | 14 649 000 | 29 950 000 | 100 % |